# Telix Pharmaceuticals

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/telix-pharmaceuticals
Canonical HTML page: https://gethealthbrief.com/entity/telix-pharmaceuticals

## Timeline

- **2026-Q4**: Interim Analysis — Expected interim efficacy data from the larger global patient cohort.
- **2026-03-10**: Primary Objectives Met — Announcement that Part 1 successfully validated safety and dosimetry profiles.
- **2025**: Enrollment Milestone — Completion of patient enrollment for the Part 1 SELECT lead-in phase.
- **2024-Q1**: Study Initiation — Launch of the ProstACT Global Phase 3 study for mCRPC.

## Recent coverage (2 stories)

### Telix’s ProstACT Phase 3 Hits Primary Goals, Advancing Prostate Cancer Therapy
2026-03-10 00:55:17 · Sentiment: Positive · Impact: 7/10 · Sources: 4

Telix Pharmaceuticals has successfully met the primary objectives for Part 1 of its global Phase 3 ProstACT study, validating the safety and dosimetry of its lead therapeutic candidate, TLX591. This milestone de-risks the antibody-based radiopharmaceutical program and clears the path for the trial's continued expansion in metastatic castration-resistant prostate cancer.
Full story: https://gethealthbrief.com/story/telix-prostact-phase-3-primary-objectives-achieved

### Lantheus and Heron Signal Long-Term Growth Amid Mixed Q4 Performance
2026-02-26 13:15:01 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for the 2025 fiscal year, balancing immediate commercial headwinds with aggressive long-term guidance. Both companies introduced fiscal year 2026 outlooks, signaling a strategic shift toward post-2025 growth catalysts and pipeline diversification.
Full story: https://gethealthbrief.com/story/lantheus-heron-q4-earnings-fy26-outlook

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.